Samik Pharmaceutical CEO Sells 20,000 Shares After Patent-Driven Surge, Reviving K-Bio Insider Trading Concerns

Young-yi Kwon, co-CEO of Samik Pharmaceutical, has drawn market attention after selling 20,000 shares on the open market shortly after the company’s stock surged following registration of a patent for a key technology. The disclosure comes as financial authorities crack down across the pharmaceutical and biotech industries on insider trading, and is expected to reignite debate over protecting minority shareholders and ensuring responsible management by executives.

Sale near a peak amid patent-driven surge

According to the electronic disclosure system on the 23rd, Young-yi Kwon, co-CEO of Samik Pharmaceutical, sold 20,000 common shares on the open market on the 17th for 11,000 won per share. The sale totaled about 220 million won, reducing Kwon’s holdings from 60,000 shares to 40,000. The ownership stake fell by 0.20 percentage points, from 0.60% to 0.40%.

The timing of the sale is at the center of the controversy. Samik Pharmaceutical’s stock surged 17.95% from the previous trading day on news that it had registered a patent on Sept. 14 related to Unisphero, a long-acting microsphere platform that converts treatments for alopecia areata and rheumatoid arthritis into once-monthly injections. The stock set a 52-week high, and trading volume reached 14.16 million shares, far above normal. Suspicions of a sale near the peak have intensified because Kwon is a professional manager in charge of R&D and is in a position to best understand the patent’s technical value.

Samik Pharmaceutical remained privately held for more than 50 years before listing on the KOSDAQ in October 2025 through a SPAC merger. Kwon is a registered director appointed on March 31, 2025, with a term through March 31, 2028. The company has 10,067,588 shares outstanding.

K-Bio insider trading crackdown intensifies

The disclosure comes amid turmoil across South Korea’s pharmaceutical and biotech industries over insider trading allegations. Just two days earlier, on Sept. 15, a joint task force of the Financial Services Commission, the Financial Supervisory Service and the Korea Exchange raided the headquarters of KOSDAQ-listed ABL Bio and the homes of employees on suspicion of using undisclosed information about a major technology export deal to make illicit gains. About 10 employees are suspected of involvement, and the estimated illicit gains total about 1 billion won. Around the same time, an executive at Frombio also drew market criticism for selling all of his shares just before the company faced the risk of being designated as an issue stock.

The joint task force said it would “strictly punish acts by insiders, including listed-company employees, who use material nonpublic information learned in the course of their duties to trade stocks, in violation of the Capital Markets Act.” It has also warned of intensive investigations into pharmaceutical and biotech executives’ front-running or profit-taking around favorable disclosures. Asian Century Stocks, an analysis firm specializing in Asian equities, also said in a recent report that “overall insider buying has increased since South Korea introduced its corporate value-up program, but insider selling in the volatile biotech sector may still be interpreted by investors as a signal of a short-term peak.”

Foreign investors have made large-scale sales in the South Korean stock market this year, but have continued selective net buying of KOSDAQ pharmaceutical and biotech companies with proven technology. Samik Pharmaceutical is also on global investors’ radar: in June, five consecutive trading days of large-scale net buying by foreign investors led the Korea Exchange to designate it as an investment-caution issue. In this context, a sale disclosure by a key executive is bound to directly affect investment decisions by foreign and institutional investors.

Short-term profit-taking pressure versus long-term technology value

In the short term, buying that flowed in on the patent news could turn into profit-taking after Kwon’s sale near the peak was disclosed. Investors may interpret an executive’s sale as a signal that the stock has reached a short-term high. The fact that the CEO leading the company’s core R&D reduced his stake immediately after the patent-driven surge will also be closely scrutinized under global ESG standards that emphasize minority shareholder protection and responsible management.

However, Samik Pharmaceutical’s long-term corporate value depends, apart from the executive’s share sale, on whether the Unisphero platform technology can lead to the commercialization of treatments for hair loss or rheumatoid arthritis. With financial authorities tightening their crackdown on insider trading across the pharmaceutical and biotech industries, stock sales by executives at KOSDAQ-listed companies are expected to decline sharply, while market transparency is expected to improve further.